AzTrials
AzTrials

Upper Aerodigestive Tract NeoplasmsH&NANCENCT07596355

AI-Assisted Endoscopy for Upper Aerodigestive Tract Lesions

An observational study of Upper Aerodigestive Tract Neoplasms and Upper AerodigestiveTract Cancer, run by Istituto Italiano di Tecnologia at 3 sites in 3 countries.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This is a prospective observational clinical study designed to evaluate the performance of artificial intelligence (AI) algorithms applied to upper aerodigestive tract (UADT) video-endoscopy. Read more about this study

Who is it for?
Ages 18 years and older
How many people
283 participants
Where
3 sitesin 3 countries
Study dates
May 2026to Feb 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The sample size for a single-arm, prospective cohort study, where the same group of patients undergoes testing with an AI model and a human physician and then they are compared with the gold standard reference test (biopsy) was calculated based on information from previous studies

Who may be able to join

  • Age > 18 years
  • Injury originating from the upper aero-digestive tract
  • Recording of the video-endoscopic examination
  • Patient known to undergo a biopsy of the lesion or clinical follow-up for lesion with known biopsy (e.g. laryngeal papillomatosis) or suffering from Reinke's edema (in this pathology, in fact, biopsy is not necessary since the diagnosis is clinical)
  • Or patients undergoing transoral lesion excision

Who cannot join

  • Submucosal lesion
  • Patients with previous operations on the upper aero-digestive tract
  • Patients with previous radiotherapy of the head and neck district
  • Poor compliance on endoscopic examination
  • Unavailability of CADe/CADx or CASe data logging note

Trial locations and contacts

3 sites in 3 countries. Contact the study team or a site near you to ask about taking part.

Leonardo De Mattos, PhD contact

+39 010 2898 270

leonardo.demattos@iit.it

3 sites in 3 countries

Belgium1 site

  • UZ Leuven

    Leuven, Flemish Brabant, 3000

    Vincent Vander Poorten, Prof. and ENT Surgeon, +32 16 33 23 42, vincent.vanderpoorten@uzleuven.be

    Vincent Vander Poorten, MD PhD

Other trials in Belgium

Italy1 site

  • IRCCS Ospedale Policlinico San Martino

    Genova, GE, 16131

    Francesco Mora, Otorhinolaryngologist and Prof, +39 010-5557479, Francesco.Mora@unige.it

    Francesco Mora, MD PhD

Other trials in Italy

Spain1 site

  • Hospital Clínic de Barcelona

    Barcelona, Barcelona, 08036

    Claudio Sampieri, Otorhinolaryngologist, +34 93 227 57 66, claudio.sampieri@outlook.com

    Claudio Sampieri, MD PhD

Other trials in Spain

About this study

Official title: Head&Neck Application of Novel Computer-assisted Endoscopy

This is a prospective observational clinical study designed to evaluate the performance of artificial intelligence (AI) algorithms applied to upper aerodigestive tract (UADT) video-endoscopy. The study assesses three main tasks: lesion detection (localization), classification (benign vs malignant), and segmentation of tumor margins.

AI algorithms will be applied to endoscopic video data acquired during routine clinical practice without influencing clinical decision-making. The system will process images in real time and store data for subsequent analysis. AI outputs will be compared with physician assessment and reference standard histopathology to evaluate diagnostic performance.

Read the detailed description

The artificial intelligence algorithms developed will be employed in the analysis of laryngeal lesions for 3 tasks:

  • Task 1: Computer aided diagnosis (CADx): the algorithm provides a differential diagnosis between benign and malignant neoplasms (binary classification) and the exact histology (multiclass classification). During the UADT video-endoscopy in the outpatient clinic, the physician performs the video-endoscopy and selects and captures n.3 WL and n.3 NBI significant frames of the lesion. The AI model records the classification output of the algorithm that the physician cannot access. The predicted pathologic results will be finally displayed as two different classifications along with the probability of each prediction (0% to 100%) as estimated by the AI algorithm: a first binary classification "neoplastic" or "non-neoplastic," and a second multiclass classification with the exact histology. The physician subsequently, based on the endoscopic examination, will write the suspected diagnosis (benign vs. malignant lesion and the actual histology) in the appropriate patient chart. Next, the physician reviews the screenshot taken and makes sure the lesion is visible in every one of them. Retrospectively, an investigator (blinded to the physician's assessment) will review the AI processed frames with the resulting CADx classifications and mark the AI-processed diagnosis in the patient chart. Once biopsied, the final histology of the lesion analyzed by definitive histopathological examination is recorded in the patient chart by the investigator. The investigators will finally compare the two recorded diagnoses (CADx and physician) with the definitive histology.
  • Task 2: Computer aided detection (CADe): the algorithm, through the representation of a rectangle (bounding box), localizes the lesion during the video-endoscopy in the outpatient clinic in real-time. During the UADT video-endoscopy, the physician performs the video-endoscopy as for standard-of-care procedure. In parallel, the AI model processes in real-time the endoscopic video and records the output of the algorithm (which the physician cannot access). The physician captures n.3 WL and n.3 NBI significant frames of the lesion. Moreover, n.3 frames where no lesions are visible are captured as negative controls. Later, the physician reviews the screenshot taken and makes sure to label the frames where the lesion is visible as "positive cases" and the frame where the lesion is not visible as "negative cases". The investigators will finally assess if the lesion was detected by the CADe system to define a "true positive". Similarly, to define a true negative, the CADe system should have not output a bounding box in the majority of the "negative cases" frames.
  • Task 3: Computer aided segmentation (CASe): the algorithm analyzes the neoplasm margins and provides a delineation mask. In the operating room setting, once the lesion to be resected is identified with a 0° telescope, the surgeon captures n.1 WL and n.1 NBI close-up photographs that exemplify the superficial lesion margins. The same procedure is repeated with a 70° optics and other two photographs are acquired. The frames taken are then saved and analyzed by the AI algorithm, which will perform the segmentation task. The surgeon will be blinded to the AI prediction. Later, the surgeon will draw the margins of the lesion according to her/his evaluation of each captured frame. The annotated frame will be saved so that it can be analyzed at a later time. Afterwards, in cases where positive superficial margins are identified by histopathologic examination, the surgeon-designed margins and the AI model ones will be compared to see if there was any difference in the suggested margin.
Medical subject headings
Head and Neck Neoplasms, Neoplasms, Carcinoma, Squamous Cell, Leukoplakia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Negative Predictive Value of the CADx Algorithm for Malignant or Premalignant Upper Aerodigestive Tract Lesions

    Negative Predictive Value (NPV) of the computer-aided diagnosis (CADx) algorithm for classifying UADT lesions as malignant/premalignant versus benign/non-neoplastic, using definitive histopathology as the reference standard. The CADx final classification will be based on the majority rule across selected white-light and narrow-band imaging frames. NPV = true negatives / (true negatives + false negatives). The pre-specified performance target is NPV ≥ 90%.

    Measured: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.

  2. Sensitivity of the CADe Algorithm for Localization of Upper Aerodigestive Tract Lesions

    Sensitivity of the computer-aided detection (CADe) algorithm for localizing UADT lesions with a bounding box. A true positive is defined as localization of the lesion area by a bounding box in the majority of physician-labeled lesion-positive captured frames. Sensitivity = true positives / (true positives + false negatives).

    Measured: At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.

  3. Median Intersection Over Union Between CASe Segmentation and Surgeon-Drawn Lesion Margins

    Median overlap between the AI-generated segmentation mask and the lesion margin area drawn by the surgeon on intraoperative endoscopic images. Intersection over Union (IoU) = area of overlap / area of union. Values range from 0 to 1; higher values indicate greater agreement.

    Measured: At intraoperative pre-resection endoscopy, with assessment performed after image annotation up to 30 days after surgery.

  4. Median Dice Similarity Coefficient Between CASe Segmentation and Surgeon-Drawn Lesion Margins

    Median Dice Similarity Coefficient (DSC) between the AI-generated segmentation mask and the lesion margin area drawn by the surgeon on intraoperative endoscopic images. Dice Similarity Coefficient = 2 × area of overlap / (AI segmented area + surgeon-drawn area). Values range from 0 to 1; higher values indicate greater agreement.

    Measured: At intraoperative pre-resection endoscopy, with assessment performed after image annotation up to 30 days after surgery.

Secondary outcomes (11)

  1. WL-NPV vs. NBI-NPV of CADx classification

    Negative Predictive Value (NPV) of CADx classification calculated using only the three selected white-light frames, compared with definitive histopathology, vs. NPV of CADx classification calculated using only the three selected narrow-band imaging frames, compared with definitive histopathology.

    The final AI-result will be calculated based on the majority rule of the 3 WL and 3 NBI frames computed separately.

    Measured: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.

  2. Clinician-Reported Usability Score for the AI Endoscopy System

    Usability of the AI endoscopy system assessed using standardized usability questionnaires administered to clinicians after use of the AI system. Questionnaire scoring will be interpreted according to the selected questionnaire manual, with higher scores indicating greater usability.

    Measured: Assessed after clinician use of the AI system during study procedures, up to 20 months after study initiation.

  3. Sensitivity, Specificity and Accuracy of CADx histology prediction

    Sensitivity, Specificity and Accuracy of the CADx algorithm for histology prediction, compared with definitive histopathology.

    Measured: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.

  4. F1 Score of CADx Classification

    F1 score of the CADx classification output compared with definitive histopathology.

    Measured: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.

  5. Area Under the Receiver Operating Characteristic Curve of CADx Classification

    AUC of the ROC curve for CADx classification of UADT lesions compared with definitive histopathology.

    Measured: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.

  6. Sensitivity, Specificity and Accuracy of human physician histology prediction

    Sensitivity, Specificity an Accuracy of the treating physician's suspected diagnosis compared with definitive histopathology.

    Measured: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.

  7. Specificity of the CADe Algorithm for Localization of Upper Aerodigestive Tract Lesions

    Proportion of physician-labeled lesion-negative frames/cases in which the CADe algorithm does not output a bounding box in the majority of negative-control frames.

    Measured: At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.

  8. Accuracy of the CADe Algorithm for Localization of Upper Aerodigestive Tract Lesions

    Overall proportion of correctly classified lesion-positive and lesion-negative cases/frames by the CADe algorithm.

    Measured: At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.

  9. Positive Predictive Value of the CADe Algorithm for Localization of Upper Aerodigestive Tract Lesions

    Positive predictive value of CADe bounding-box output for lesion localization. PPV = true positives / (true positives + false positives).

    Measured: At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.

  10. Negative Predictive Value of the CADe Algorithm for Localization of Upper Aerodigestive Tract Lesions

    Negative predictive value of CADe absence of bounding-box output for lesion localization. NPV = true negatives / (true negatives + false negatives).

    Measured: At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.

  11. Percentage of Positive Superficial Margin Cases in Which the AI-Predicted Tumor Area Is Wider Than the Surgeon-Drawn Area

    Among cases with positive superficial margins on final histopathology, percentage of cases in which the AI-predicted tumor area extends beyond the surgeon-drawn margin at the affected margin.

    Measured: At intraoperative pre-resection endoscopy, with assessment performed after image annotation up to 30 days after surgery.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 May 2026
  2. Study startMay 2026 (estimated)
  3. Primary completionDec 2027 (estimated)
  4. Study completionFeb 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
283 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07596355
Sponsor's protocol ID
IIT_AIRCARE_H&NANCE
Acronym
H&NANCE
Status last verified
May 2026
First submitted
5 May 2026
Last updated
19 May 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Dunham ME, Kong KA, McWhorter AJ, Adkins LK. Optical Biopsy: Automated Classification of Airway Endoscopic Findings Using a Convolutional Neural Network. Laryngoscope. 2022 Feb;132 Suppl 4:S1-S8. doi: 10.1002/lary.28708. Epub 2020 Apr 28.

    PubMed 32343434

  • Piazza C, Peretti G, Vander Poorten V. Editorial: Advances in Transoral Approaches for Laryngeal Cancer. Front Oncol. 2018 Oct 17;8:455. doi: 10.3389/fonc.2018.00455. eCollection 2018. No abstract available.

    PubMed 30386742

  • Paderno A, Piazza C, Del Bon F, Lancini D, Tanagli S, Deganello A, Peretti G, De Momi E, Patrini I, Ruperti M, Mattos LS, Moccia S. Deep Learning for Automatic Segmentation of Oral and Oropharyngeal Cancer Using Narrow Band Imaging: Preliminary Experience in a Clinical Perspective. Front Oncol. 2021 Mar 24;11:626602. doi: 10.3389/fonc.2021.626602. eCollection 2021.

    PubMed 33842330

  • Azam MA, Sampieri C, Ioppi A, Africano S, Vallin A, Mocellin D, Fragale M, Guastini L, Moccia S, Piazza C, Mattos LS, Peretti G. Deep Learning Applied to White Light and Narrow Band Imaging Videolaryngoscopy: Toward Real-Time Laryngeal Cancer Detection. Laryngoscope. 2022 Sep;132(9):1798-1806. doi: 10.1002/lary.29960. Epub 2021 Nov 25.

    PubMed 34821396

  • Ren J, Jing X, Wang J, Ren X, Xu Y, Yang Q, Ma L, Sun Y, Xu W, Yang N, Zou J, Zheng Y, Chen M, Gan W, Xiang T, An J, Liu R, Lv C, Lin K, Zheng X, Lou F, Rao Y, Yang H, Liu K, Liu G, Lu T, Zheng X, Zhao Y. Automatic Recognition of Laryngoscopic Images Using a Deep-Learning Technique. Laryngoscope. 2020 Nov;130(11):E686-E693. doi: 10.1002/lary.28539. Epub 2020 Feb 18.

    PubMed 32068890

  • Kim DH, Kim Y, Kim SW, Hwang SH. Use of narrowband imaging for the diagnosis and screening of laryngeal cancer: A systematic review and meta-analysis. Head Neck. 2020 Sep;42(9):2635-2643. doi: 10.1002/hed.26186. Epub 2020 May 4.

    PubMed 32364313

  • Rex DK, Kahi C, O'Brien M, Levin TR, Pohl H, Rastogi A, Burgart L, Imperiale T, Ladabaum U, Cohen J, Lieberman DA. The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on real-time endoscopic assessment of the histology of diminutive colorectal polyps. Gastrointest Endosc. 2011 Mar;73(3):419-22. doi: 10.1016/j.gie.2011.01.023.

    PubMed 21353837

Questions about this trial

What is this clinical trial studying?

An observational study of Upper Aerodigestive Tract Neoplasms and Upper AerodigestiveTract Cancer, run by Istituto Italiano di Tecnologia at 3 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Belgium, Italy, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Leonardo De Mattos, PhD (+39 010 2898 270, leonardo.demattos@iit.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Negative Predictive Value of the CADx Algorithm for Malignant or Premalignant Upper Aerodigestive Tract Lesions (time frame: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07596355, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in